IMCR 250117 30.00P (IMCR250117P30000) Stock Options, News & Quotes

US OptionsDetailed Quotes

IMCR250117P30000

Watchlist

1.05
-1.95-65.00%

15min DelayClose Jan 17 16:00 ET

1.05High1.05Low

Intraday

5D
Daily

News

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's Is How to Trade
Zacks Jan 13 09:00 ET
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Moomoo NewsJan 13 06:31 ET · Ratings
J.P. Morgan Maintains Immunocore(IMCR.US) With Buy Rating
Moomoo NewsJan 12 21:31 ET · Ratings
Needham Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $71
Moomoo NewsJan 10 11:32 ET · Ratings
Immunocore Holdings Positioned for Growth With Strategic 2025 Priorities and Strong Financial Outlook
TipRanksJan 10 10:35 ET
Immunocore Reports Cash, Equivalents of $820M as of December 31
TipRanksJan 10 07:31 ET

Comments

Meltyy

May 16, 2024 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Meltyy

May 12, 2024 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3...

Moomoo AI

Dec 18, 2023 07:59

Immunocore Holdings' P/S ratio aligns with industry peers, but its projected revenue growth lags behind sector-wide forecasts, indicating a potential realignment. Current market sentiment may be too optimistic, posing potential disappointment for investors if the P/S ratio follows the growth outlook.

What Immunocore Holdings Plc's (NASDAQ:IMCR) 37% Share Price Gain Is Not Telling You

Moomoo AI

Nov 25, 2023 15:36

JP Morgan predicts growth for Insmed due to recent study updates, potential rise of Denali shares ahead of 2025 readouts, and an upside for Immunocore shares following a 'strong' oncology drug launch. Crinetics could also benefit from upcoming catalysts.

JP Morgan Bullish on Six Big Biotechs, Rates Nine Others Neutral or Lower

Moomoo Breakfast US

Jul 18, 2022 07:51

Columns Today's pre-market stock movers: GS, BA, BAC, BABA and more

Gainers:
In reaction to earnings/guidance:
• $The ODP (ODP.US)$ +8.03% (The ODP Corporation gains on guiding Q2 and FY22 earnings above the consensus; to buyback shares of $600M)
• $Synchrony Financial (SYF.US)$ +4.2%(The financial services company posted adjusted earnings per share of $1.60 for the June ended quarter, beating analysts' estimates of $1.41 per share, according to FactSet.)
• $Goldman Sachs (GS.US)$ +4.2% (Goldman Sachs beats...